Liver tumour management presents a complex challenge to oncologists and multidisciplinary treatment teams. Selective internal radiation therapy (SIRT) with SIR-Spheres® Y-90 resin microspheres administered by interventional radiologists is an approved local approach to managing liver tumours. Approximately 80,000 doses have been administered in more than 1,090 treatment centres worldwide.
In addition, new data from an array of large, multi-centre, international studies may support expanded use of SIR-Spheres Y-90 resin microspheres in appropriate patients. Results of the SIRFLOX study published in 2016 in the Journal of Clinical Oncology, show particular promise. New first-line mCRC data from the 1100-patient combined SIRFLOX, FOXFIRE and FOXFIRE Global studies will be presented in the first half of 2017. In HCC, results from SARAH and SIRveNIB are also due in 2017 and results from the SORAMIC study are expected in 2018.